MVK gene abnormality and new approach to treatment of hyper IgD syndrome and periodic fever syndrome

Japanese Journal of Clinical Immunology

Volumn 30, Issue 2, 2007, Pages 86-89

  Naruto, Takuya ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Hyper IgD syndrome and periodic fever syndrome; Inlammation; Isoprenoid pathway; Mevalonate kinase; Mevalonic aciduria

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN D; MEVALONATE KINASE; PHOSPHOTRANSFERASE;

ARTICLE; BLOOD; FAMILIAL MEDITERRANEAN FEVER; GENETICS; HUMAN; HYPERGAMMAGLOBULINEMIA; MUTATION; SYNDROME;

FAMILIAL MEDITERRANEAN FEVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN D; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SYNDROME;

EID: 34447134170     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.30.86     Document Type: Article

References (28)

1. Stojanov S and Kastner DL.: Familial autoinflammatory diseases: Genetics, pathogenesis and treatment. Curr. Opin. Rheumatol. 17: 586–599, 2005.
2. Drenth JP, Cuisset L, Grateau G, et al.: Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat. Genet. 22: 178–181, 1999.
3. Cuisset L, Drenth JP, Simon A, et al.: Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur. J. Hum. Genet. 9: 260–266, 2001.
4. Houten SM, Koster J, Romeijn GJ, et al.: Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome. Eur. J. Hum. Genet. 9: 253–259, 2001.
5. Simon A, Mariman EC, van der Meer JW, et al.: A founder effect in the hyperimmunoglobulinemia D and periodic fever syndrome. Am. J. Med. 114: 148–152, 2003.
6. Houten SM, van Woerden CS, Wijburg FA, et al.: Carrier frequency of the V377I (1129G> A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur. J. Hum. Genet. 11: 196–200, 2003.
7. Houten SM, Schneiders MS, Wanders RJ, et al.: Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J. Biol. Chem. 278: 5736–5743, 2003.
8. Hofmann GF, Charpentier C., Mayatepek E, et al.: Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91: 915–921, 1993.
9. Haas D and Hofmann GF.: Mevalonate kinase deiciencies: From mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet.J.Rare. Dis. 1: 13, 2006.
10. Houten SM, Kuis W, Duran M, et al.: Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 22: 175–177, 1999.
11. Houten SM, Romeijn GJ, Koster J, et al.: Identiication and characterization of three novel missense mutations in mevalonate kinase cDNA causing mevalonic aciduria, a disorder of isoprene biosynthesis. Hum. Mol. Genet. 8: 1523–1528, 1999.
12. Kelley RI and Herman GE.: Inborn errors of sterol biosynthesis. Annu. Rev. Genomics Hum. Genet. 2: 299–341, 2001.
13. Mandey SH, Schneiders MS, Koster J, et al.: Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deiciency. Hum. Mutat. 27: 796–802, 2006.
14. Simon A, Kremer HP, Wevers RA, et al.: Mevalonate kinase deiciency: Evidence for a phenotypic continuum. Neurology 62: 994–997, 2004.
15. Galeazzi M, Gasbarrini G, Ghirardello A, et al.: Autoinlammatory syndromes. Clin. Exp. Rheumatol. 24: S79-S85, 2006.
16. Goldstein JL and Brown MS.: Regulation of the mevalonate pathway. Nature 343: 425–430, 1990.
17. Houten SM, Frenkel J, Waterham HR.: Isoprenoid biosynthesis in hereditary periodic fever syndromes and inlammation. Cell Mol. Life Sci. 60: 1118–1134, 2003.
18. Hoffmann GF, Wiesmann UN, Brendel S, et al.: Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway fibroblasts from patients with mevalonate kinase deiciency. Pediatr. Res. 41: 541–546, 1997.
19. Hubner C., Hofmann GF, Charpentier C., et al.: Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deiciency. Pediatr. Res. 34: 129–133, 1993.
20. Medlej-Hashim M, Petit I, Adib S, et al.: Familial Mediterranean Fever: Association of elevated IgD plasma levels with specific MEFV mutations. Eur. J. Hum. Genet. 9: 849–854, 2001.
21. Houten SM, Frenkel J, Rijkers GT, et al.: Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum. Mol. Genet. 11: 3115–3124, 2002.
22. Simon A, Drewe E, van der Meer JW, et al.: Simvastatin treatment for inlammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin. Pharmacol. Ther. 75: 476–483, 2004.
23. Takada K, Aksentijevich I, Mahadevan V, et al.: Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 48: 2645–2651, 2003.
24. Demirkaya E, Caglar MK, Waterham HR, et al.: A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin. Rheumatol. 2006.
25. Marchetti F, Barbi E, Tommasini A, et al.: In-efficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. Clin.Exp.Rheumatol. 22: 791–792, 2004.
26. Drenth JP, van der Meer JW, Kushner I.: Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. J. Immunol. 157: 400–404, 1996.
27. Bodar EJ, van der Hilst JC, Drenth JP, et al.: Efect of etanercept and anakinra on inlammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model. Neth. J. Med. 63: 260–264, 2005.
28. Cailliez M, Garaix F, Rousset-Rouviere C., et al.: Anakinra is safe and efective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab Dis. 29: 763, 2006.